Open AccessClinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center
Author(s) -
Weiss Jennifer A.,
Nicklawsky Andrew,
Kagihara Jodi A.,
Gao Dexiang,
Fisher Christine,
Elias Anthony,
Borges Virginia F.,
Kabos Peter,
Davis Sarah L.,
Leong Stephen,
Eckhardt Sue Gail,
Diamond Jennifer R.
Publication year - 2020
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.3487
Subject(s) - medicine , breast cancer , metastatic breast cancer , cancer , clinical trial , chemotherapy , oncology , cohort , retrospective cohort study , surgery
Patients with metastatic breast cancer (MBC) refractory to standard of care therapies have a poor prognosis. The purpose of this study was to assess patient characteristics and clinical outcomes for patients with MBC treated on phase I clinical trials. We performed a retrospective review of all patients with MBC who were enrolled in phase I clinical trials at the University of Colorado Cancer Center from January 2012 to June 2018. A total of 208 patients were identified. Patients had a mean age of 57 years and received on average 2.1 (range 0‐10) prior lines of chemotherapy. The majority of patients had hormone receptor‐positive/HER2‐negative breast cancer (58.6%) and 30.3% had triple‐negative breast cancer. The median progression free survival (PFS) was 2.8 months (95% CI, 2.3‐3.9) and median overall survival (OS) was 11.5 months (95% CI, 9.6‐13.2). Independent factors associated with longer PFS in multivariable analysis were treatment in a breast cancer‐selective trial or cohort ( p = 0.016), age >50 years ( p = 0.002), and ≤2 prior lines of chemotherapy in the metastatic setting ( p = 0.025). Phase I clinical trials remain a valuable option for select patients with MBC and enrollment should be encouraged when available.